Levobetaxolol is the S-enantiomer of betaxolol, a selective beta-adrenergic receptor blocking compound used in ophthalmic pharmaceutical applications. It belongs to the beta-blocker class and reduces aqueous humor production in the eye, thereby helping to lower elevated intraocular pressure.
Levobetaxolol acts primarily by blocking β1-adrenergic receptors and has been developed for topical ophthalmic administration. The compound is associated with reduced aqueous humor formation and is used in the management of ocular hypertension and glaucoma.
Levobetaxolol has the molecular formula C18H29NO3 and a molecular weight of approximately 307.43 g/mol. The CAS Number for Levobetaxolol is 93233-54-8.
It is the levorotatory enantiomer of betaxolol and may be encountered in pharmaceutical development in its free-base form or as an appropriate pharmaceutical salt depending on the formulation.
Levobetaxolol is a selective β-adrenergic receptor antagonist, with preferential activity at β1 receptors.
When administered ophthalmically, beta-adrenergic blockade reduces the production of aqueous humor by the ciliary body. The resulting reduction in aqueous humor formation lowers intraocular pressure and provides the pharmacological basis for its use in glaucoma and ocular hypertension.
Levobetaxolol has been investigated and used in ophthalmic formulations for the reduction of elevated intraocular pressure associated with open-angle glaucoma and ocular hypertension.
Its ophthalmic application makes it relevant to the development and manufacture of topical eye-drop formulations.
Levobetaxolol API can be evaluated using validated analytical procedures for identity, assay, related substances, water content, residual solvents, elemental impurities and other applicable quality attributes.
For ophthalmic pharmaceutical applications, additional controls may apply depending on the dosage form, including microbial quality, particulate matter and other requirements applicable to sterile ophthalmic products.
Acceptance criteria should be based on the applicable manufacturer's drug-substance specification, Certificate of Analysis and relevant regulatory requirements.
Levobetaxolol should be stored in a tightly closed pharmaceutical-grade container under controlled conditions. It should be protected from excessive heat, moisture and direct light. Specific storage requirements should follow the applicable manufacturer's approved specification.
Levobetaxolol API may be supplied for qualified ophthalmic pharmaceutical manufacturing, formulation development, analytical and research applications, subject to applicable quality and regulatory requirements.
Levobetaxolol API is available for qualified pharmaceutical development and manufacturing requirements subject to applicable quality and regulatory standards. Customers can request product specifications, Certificate of Analysis, analytical documentation, packaging information and commercial details according to their requirements.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | ≤ 1.5% |
| Water Content | NMT 1.0% |